4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares, rose in value on Wednesday, June 18, with the stock price down by -1.45% to the previous day’s close as strong demand from buyers drove the stock to $4.09.
Actively observing the price movement in the last trading, the stock closed the session at $4.15, falling within a range of $4.05 and $4.255. The value of beta (5-year monthly) was 2.83. Referring to stock’s 52-week performance, its high was $28.93, and the low was $2.23. On the whole, FDMT has fluctuated by 7.63% over the past month.
With the market capitalization of 4D Molecular Therapeutics Inc currently standing at about $189.47 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that FDMT’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of FDMT currently trading nearly 2.65% and 16.35% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.57, while the 7-day volatility ratio is showing 2.03% which for the 30-day chart, stands at 4.95%. Furthermore, 4D Molecular Therapeutics Inc (FDMT)’s beta value is 2.83, and its average true range (ATR) is 0.30.
A comparison of 4D Molecular Therapeutics Inc (FDMT) with its peers suggests the former has fared considerably weaker in the market. FDMT showed an intraday change of -1.45% in last session, and over the past year, it shrunk by -82.69%%.
Data on historical trading for 4D Molecular Therapeutics Inc (NASDAQ:FDMT) indicates that the trading volumes over the past 10 days have averaged 0.53 and over the past 3 months, they’ve averaged 597.95K. According to company’s latest data on outstanding shares, there are 46.32 million shares outstanding.
Nearly 10.31% of 4D Molecular Therapeutics Inc’s shares belong to company insiders and institutional investors own 88.02% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.35 million shares as on 2025-05-30, resulting in a short ratio of 9.5. According to the data, the short interest in 4D Molecular Therapeutics Inc (FDMT) stood at 978.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 5.04 million. The stock has fallen by -26.57% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the FDMT stock heading into the next quarter.
